Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
Abstract Background The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance t...
Main Authors: | Joseph R. Calabrese, Na Jin, Brian Johnson, Pedro Such, Ross A. Baker, Jessica Madera, Peter Hertel, Jocelyn Ottinger, Joan Amatniek, Hiroaki Kawasaki |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-06-01
|
Series: | International Journal of Bipolar Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40345-018-0122-z |
Similar Items
-
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
by: Michele Wilson, et al.
Published: (2016-03-01) -
Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
by: Cuomo I, et al.
Published: (2018-06-01) -
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
by: Such P, et al.
Published: (2021-06-01) -
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
by: Sally Mustafa, et al.
Published: (2019-04-01) -
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
by: Christophe Sapin, et al.
Published: (2016-09-01)